Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company A2A Pharmaceuticals LLC
DescriptionN-acetylglucosamine deacetylase (LpxC) inhibitor
Molecular Target UDP-3-O-[3-hydroxymyristoyl] N-acetylglucosamine deacetylase (LpxC)
Mechanism of Action 
Therapeutic Modality 
Latest Stage of DevelopmentPreclinical
Standard IndicationGram-negative bacterial infection
Indication DetailsTreat mutlidrug-resistant Gram-negative bacterial infections
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today